Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $99.87, but opened at $108.80. Kymera Therapeutics shares last traded at $119.5040, with a volume of 943,860 shares changing hands.
Kymera Therapeutics News Summary
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
- Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
- Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
- Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing
Wall Street Analyst Weigh In
KYMR has been the topic of a number of analyst reports. Brookline Capital Markets restated a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. UBS Group boosted their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Citigroup increased their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Stephens raised their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.18.
Kymera Therapeutics Stock Down 7.2%
The firm has a market cap of $8.89 billion, a PE ratio of -30.29 and a beta of 2.02. The company has a 50-day simple moving average of $84.81 and a two-hundred day simple moving average of $82.31.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.82) EPS. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.
Insider Buying and Selling
In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of Kymera Therapeutics stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the sale, the director owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. The trade was a 86.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce Booth sold 262,637 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $115.39, for a total transaction of $30,305,683.43. Following the completion of the transaction, the director owned 564,668 shares in the company, valued at approximately $65,157,040.52. The trade was a 31.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,950,983 shares of company stock worth $311,898,929. Insiders own 15.98% of the company’s stock.
Hedge Funds Weigh In On Kymera Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. US Bancorp DE increased its position in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after buying an additional 166 shares during the last quarter. Glenmede Trust Co. NA lifted its position in shares of Kymera Therapeutics by 3.6% during the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after buying an additional 235 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after buying an additional 252 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares during the period. Finally, Swiss National Bank increased its holdings in Kymera Therapeutics by 0.3% in the 1st quarter. Swiss National Bank now owns 94,500 shares of the company’s stock worth $7,871,000 after acquiring an additional 300 shares during the last quarter.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Featured Articles
- Five stocks we like better than Kymera Therapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
